Physician profile
Ernest Waller
NPI 1427047745
$14,122.83
in general payments reported to CMS, 2019-2025
45 companies · $1,796 in 2025
The $1,796 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,235 · 2020: $1,330 · 2021: $1,207 · 2022: $2,193 · 2023: $5,244 · 2024: $1,117 · 2025: $1,796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,455 · Education: $3,045 · Travel and Lodging: $1,658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,454.54 |
| Education | $3,045.18 |
| Travel and Lodging | $1,657.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,013.96 | 2022-2025 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $1,597.16 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Actelion Pharmaceuticals US, INC. | $1,176.03 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Insmed, INC. | $866.97 | 2019-2025 | Arikayce, Brinsupri |
| Glaxosmithkline, LLC. | $824.73 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $759.31 | 2019-2025 | Ofev |
| United Therapeutics Corporation | $335.59 | 2020-2025 | Tyvaso, Tyvaso |
| Grifols USA, LLC | $330.69 | 2019-2025 | Prolastin-C Liquid |
| Amgen INC. | $301.98 | 2023-2025 | Tezspire, Tavneos |
| Genzyme Corporation | $296.33 | 2021-2025 | |
| Axsome Therapeutics, INC. | $129.11 | 2024-2025 | Sunosi |
| Philips North America LLC | $124.34 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.41 | 2020-2024 | Glassia |
| Sunovion Pharmaceuticals INC. | $115.86 | 2019-2021 | |
| Abbvie INC. | $96.23 | 2021-2023 | Avycaz, Teflaro |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Waller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.